These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24768013)

  • 1. Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data.
    Witjes JA; Gomella LG; Stenzl A; Chang SS; Zaak D; Grossman HB
    Urology; 2014 Jul; 84(1):122-6. PubMed ID: 24768013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
    Yang LP
    Mol Diagn Ther; 2014 Feb; 18(1):105-16. PubMed ID: 24248555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blue Light Cystoscopy: Indications and Outcomes.
    Pohar KS
    Curr Urol Rep; 2020 Apr; 21(5):19. PubMed ID: 32248340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
    Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
    Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
    Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
    J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.
    Geavlete B; Multescu R; Georgescu D; Geavlete P
    J Endourol; 2009 Jun; 23(6):977-81. PubMed ID: 19473068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
    Williams SB; Gavaghan MB; Fernandez A; Daneshmand S; Kamat AM
    Urol Oncol; 2022 Jan; 40(1):10.e7-10.e12. PubMed ID: 34158205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix].
    Abascal Junquera JM; Hevia Suárez M; Abascal García JM; Estébanez C; Astudillo A; Abascal R
    Arch Esp Urol; 2008 May; 61(4):475-82; discussion 482-3. PubMed ID: 18592765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study.
    Pohar KS; Patel S; Lotan Y; Trabulsi E; Woods M; Downs T; Huang WC; Jones J; Taylor J; O'Donnell M; Bivalacqua TJ; DeCastro J; Steinberg G; Kamat AM; Resnick MJ; Konety B; Schoenberg M; Jones JS; Daneshmand S;
    Urol Oncol; 2022 Aug; 40(8):382.e1-382.e6. PubMed ID: 35750559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.
    Daneshmand S; Bazargani ST; Bivalacqua TJ; Holzbeierlein JM; Willard B; Taylor JM; Liao JC; Pohar K; Tierney J; Konety B;
    Urol Oncol; 2018 Aug; 36(8):361.e1-361.e6. PubMed ID: 29859728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
    Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
    Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
    Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
    BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?
    Loidl W; Schmidbauer J; Susani M; Marberger M
    Eur Urol; 2005 Mar; 47(3):323-6. PubMed ID: 15716195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
    Dansk V; Malmström PU; Bläckberg M; Malmenäs M
    Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
    Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
    Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.